<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03185832</url>
  </required_header>
  <id_info>
    <org_study_id>C2076</org_study_id>
    <nct_id>NCT03185832</nct_id>
  </id_info>
  <brief_title>Heart Failure and Sudden Cardiac Death Japan Registry</brief_title>
  <acronym>HINODE</acronym>
  <official_title>Heart Failure Indication and Sudden Cardiac Death Prevention Trial Japan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ICON Clinical Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this observational registry is to collect clinical events and outcome data in
      4 different study populations (cohorts), with a majority of Japanese subjects, that are at
      risk of sudden cardiac death (SCD) and heart failure (HF) events. These event rates will be
      compared with available published data mainly from Europe and the United States.

      Selected Subject Cohorts:

        1. Selected subject cohort with criteria for SCD (without spontaneous prior ventricular
           sustained arrhythmia) and de novo ICD device treatment.

        2. Selected subject cohort with criteria for SCD and widely accepted standard cardiac
           resynchronization therapy (CRT) indication who received a de novo CRT-D device
           treatment.

        3. Selected subject cohort who are clinically expected to require &gt;40% right ventricular
           pacing with a left ventricular ejection fraction (LVEF) ≤50%, any determined New York
           Heart Association (NYHA) Class, and receiving pacemaker (PM) or CRT pacemaker (CRT-P)
           therapy despite previous device history (de novo, box changes, system revisions or
           upgrades).

        4. Selected subject cohort with criteria for SCD fulfilling European Society of Cardiology
           (ESC) ICD or CRT-D therapy guidelines (2016) with an LVEF ≤35%, having 2 to 5 predefined
           SCD risk factors but do not have or had have a cardiac implanted defibrillator, CRT-D,
           PM, or CRT-P.

      The primary endpoint will report on the Composite rate of first appropriately treated
      ventricular arrhythmia (by anti-tachycardia pacing [ATP] or shock) or life-threatening
      symptoms associated to ventricular arrhythmia (defined as hemodynamic instability which
      requires treatment), whichever comes first under MADIT RIT Arm B or C programming conditions
      in a study population with a majority of Japanese subjects. This primary end point is
      assessed in the ICD/CRT-D implanted patient cohort.

      The all-cause mortality in subjects with a maximum of 3 risk factors (analyzed for MADIT II
      data) will be assessed in the PM/CRT-P patient cohort.

      The All-cause mortality will be assessed in the non-implanted subject cohort.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 21, 2017</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Composite rate of first appropriately treated ventricular arrhythmia in the Defibrillator Cohort (ICD and CRT-D Cohorts)</measure>
    <time_frame>12 months follow up</time_frame>
    <description>Composite rate of first appropriately treated ventricular arrhythmia (by anti tachycardia pacing [ATP] or shock) or life-threatening symptoms associated to ventricular arrhythmia (defined as hemodynamic instability which requires treatment), whichever comes first under MADIT Arm B or C programming conditions in a study population with a majority of Japanese subjects.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>All-cause mortality in the PM/CRT-P Cohort</measure>
    <time_frame>12 months follow up</time_frame>
    <description>All-cause mortality in subjects with a maximum of 3 risk factors (analyzed for MADIT II data)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>All-cause mortality in the Non-device Cohort</measure>
    <time_frame>12 months follow up</time_frame>
    <description>All-cause mortality in the subject cohort with 2 to 5 predefined SCD driving risk factors</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality in the Defibrillator Cohort (ICD and CRT-D)</measure>
    <time_frame>12 months follow up</time_frame>
    <description>All-cause mortality rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite rate of HF events in the ICD, CRT-D, and PM/CRT-P Cohorts</measure>
    <time_frame>12 months follow up</time_frame>
    <description>Composite rate of HF events, which require intravenous (IV) treatment and/or HF related hospitalization, or which led to HF death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of rate of sudden cardiac death rate in the ICD, CRT-D, and Non-device Cohorts</measure>
    <time_frame>12 months follow up</time_frame>
    <description>Comparison of rate of sudden cardiac death in the non-device cohort with the rate of appropriately treated ventricular arrhythmias or sudden cardiac death in the defibrillator cohort (including ICD and CRT-D Cohorts)</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">355</enrollment>
  <condition>Heart Failure</condition>
  <condition>Arrhythmias, Cardiac</condition>
  <condition>Sudden Cardiac Death</condition>
  <arm_group>
    <arm_group_label>CRT-D Cohort</arm_group_label>
    <description>Composite rate of first appropriately treated ventricular arrhythmia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ICD Cohort</arm_group_label>
    <description>Composite rate of first appropriately treated ventricular arrhythmia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PM / CRT-P Cohort</arm_group_label>
    <description>All cause mortality</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-device Cohort</arm_group_label>
    <description>All-cause mortality in the subject cohort with 2 to 5 predefined SCD driving risk factors</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CRT-D</intervention_name>
    <description>This subject cohort is made by all patients enrolled and implanted with defibrillator with CRT capabilities</description>
    <arm_group_label>CRT-D Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ICD</intervention_name>
    <description>This subject cohort is made by all patients enrolled and implanted with defibrillator capabilities</description>
    <arm_group_label>ICD Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PM / CRT-P</intervention_name>
    <description>This subject cohort is made by all patients enrolled and implanted with pacemakers with or without CRT capabilities</description>
    <arm_group_label>PM / CRT-P Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non-device</intervention_name>
    <description>Patient enrolled but not implanted with a Defibrillator or Pacemaker</description>
    <arm_group_label>Non-device Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The subjects enrolled in this observational registry are from the general population seen
        by enrolling physicians at primary care clinic.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        General Inclusion Criteria:

          1. Subject is aged 20 or above

          2. Subject is willing and capable of providing informed consent

          3. Subject is willing and capable of participating in all visits associated with this
             study at an approved clinical study site and at the intervals defined by this CIP

          4. Measured Ejection fraction value obtained by echocardiography or equivalent method as
             SOC:

               -  Device cohorts: within the last 3 months prior to enrolment

               -  Non-device cohort: latest available within the last 12 months prior to enrollment
                  in case there was no documented HF decompensation, MI or revascularization,
                  otherwise within the last 3 months prior to enrollment

        And 12 lead ECG recording available as SOC:

          -  Device cohorts: pre-implant ECG maximum 45 days before implant; post-implant ECG

          -  Non-device cohort: latest available maximum 12 months prior to enrollment and subject
             agrees in the data being used for this study

        General Exclusion Criteria:

          1. Subject is enrolled in any other concurrent study without prior written approval from
             BSC, with the exception of local mandatory governmental registries and observational
             studies/registries that are not in conflict and do not affect the following:

               -  Schedule of procedures for the HINODE Study (i.e. should not cause additional or
                  missed visits)

               -  HINODE Study outcome

               -  Conduct of the HINODE Study per Good Clinical Practice /International Standard
                  Organization 14155:2011/local regulations as applicable

          2. Device implant revision is scheduled due to unstable result of an implant &lt;45 days
             prior enrolment

          3. Subjects with more than 5 of the following risk factors: LVEF &lt;35%, NYHA Class III or
             IV, LBBB with QRS &gt; 130 ms or QRS ≥150 ms, renal dysfunction (chronically BUN &gt;26
             mg/dL / ≥9.28 mmol/L), diabetes type I and II, chronic atrial fibrillation (permanent
             or persistent according to ESC Guideline 2016), prior MI, age &gt;70 years, smoking today
             or during last 5 years

          4. Subjects with chronic renal disease with chronic BUN ≥50mg/dL or creatinine ≥2.5 mg/dL

          5. Subjects with coronary artery bypass graft (CABG) surgery or percutaneous coronary
             intervention (PCI) within the past three calendar months prior to enrollment

          6. Subjects with enzyme-positive myocardial infarction within the past three calendar
             months prior to enrollment

          7. Subjects who are expected to survive for &lt;1 year with good functional status

          8. Subject's physician does not allow participation

          9. Subject is not willing and capable of participating in all testing or visits
             associated with this clinical study at an approved clinical study center and at the
             intervals defined by this CIP

         10. Unwilling to sign the consent for participation

         11. Women of childbearing potential who are or might be pregnant at the time of study
             enrolment

         12. ICD and CRT-D cohorts: implanted with a non-BSC device system. PM/CRT-P cohorts:
             implanted with a non-BSC PG device.

        Additional eligibility criteria apply to each cohort
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kazutaka Aonuma, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Tsukuba Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ichinomiya Municipal Hospital</name>
      <address>
        <city>Ichinomiya</city>
        <state>Aichi</state>
        <zip>491-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nagoya University Hospital</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>466-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Japanese Red Cross Nagoya Daini Hospital</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>466-8650</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toho University Sakura Medical Center</name>
      <address>
        <city>Sakura</city>
        <state>Chiba</state>
        <zip>285-8741</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juntendo University Urayasu Hospital</name>
      <address>
        <city>Urayasu</city>
        <state>Chiba</state>
        <zip>279-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fukuoka Tokushukai Hospital</name>
      <address>
        <city>Kasuga</city>
        <state>Fukuoka</state>
        <zip>816-0864</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sapporo Medical University Hospital</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-8543</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sapporo Higashi Tokushukai Hospital</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>065-0033</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansai Rosai Hospital</name>
      <address>
        <city>Amagasaki</city>
        <state>Hyogo</state>
        <zip>660-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hyogo Brain and Heart Center</name>
      <address>
        <city>Himeji</city>
        <state>Hyogo</state>
        <zip>670-0981</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hitachi General Hospital</name>
      <address>
        <city>Hitachi</city>
        <state>Ibaraki</state>
        <zip>317-0077</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tsukuba Hospital</name>
      <address>
        <city>Tsukuba</city>
        <state>Ibaraki</state>
        <zip>305-8576</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Marianna University School of Medicine Hospital</name>
      <address>
        <city>Kawasaki</city>
        <state>Kanagawa</state>
        <zip>216-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yokohama Rosai Hospital</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>222-0036</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yokohama Minami Kyousai Hospital</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>236-0037</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Marianna University School of Medicine, Yokohama City Seibu Hospital</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>241-0811</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tohoku University Hospital</name>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <zip>980-8574</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cerebral and Cardiovascular Center Hospital</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <zip>564-8565</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jichi Medical University Hospital</name>
      <address>
        <city>Shimotsuke</city>
        <state>Tochigi</state>
        <zip>329-0498</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Medical and Dental University Medical Hospital</name>
      <address>
        <city>Bunkyo</city>
        <state>Tokyo</state>
        <zip>113-8519</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nippon Medical School Hospital</name>
      <address>
        <city>Bunkyō</city>
        <state>Tokyo</state>
        <zip>113-8603</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's International Hospital</name>
      <address>
        <city>Chuo</city>
        <state>Tokyo</state>
        <zip>104-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toho University Ohashi Medicine Center</name>
      <address>
        <city>Meguro</city>
        <state>Tokyo</state>
        <zip>153-8515</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Metropolitan Hiroo Hospital</name>
      <address>
        <city>Shibuya</city>
        <state>Tokyo</state>
        <zip>150-0013</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toho University Omori Medical Center</name>
      <address>
        <city>Ōta</city>
        <state>Tokyo</state>
        <zip>143-8541</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yamaguchi University Hospital</name>
      <address>
        <city>Ube</city>
        <state>Yamaguchi</state>
        <zip>755-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kokura Memorial Hospital</name>
      <address>
        <city>Fukuoka</city>
        <zip>802-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyushu University Hospital</name>
      <address>
        <city>Fukuoka</city>
        <zip>812-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Okayama University Hospital</name>
      <address>
        <city>Okayama</city>
        <zip>700-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sakurabashi Watanabe Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>530-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka General Medical Center</name>
      <address>
        <city>Osaka</city>
        <zip>558-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jichi Medical University Saitama Medical Center</name>
      <address>
        <city>Saitama</city>
        <zip>330-8503</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Japanese Red Cross Saitama Hospital</name>
      <address>
        <city>Saitama</city>
        <zip>330-8553</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>June 12, 2017</study_first_submitted>
  <study_first_submitted_qc>June 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2017</study_first_posted>
  <last_update_submitted>April 29, 2020</last_update_submitted>
  <last_update_submitted_qc>April 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hear failure</keyword>
  <keyword>Sudden Cardiac Death</keyword>
  <keyword>Arrhythmia</keyword>
  <keyword>Implanted device</keyword>
  <keyword>ICD</keyword>
  <keyword>CRT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Arrhythmias, Cardiac</mesh_term>
    <mesh_term>Death, Sudden, Cardiac</mesh_term>
    <mesh_term>Death</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

